the package insert of the medicine is Combivent.
Treatment of bronchospasm associated with chronic obstructive pulmonary disease, moderate and severe in patients who require more than one bronchodilator.
When should I not use?
In patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives.
How to use?
Adults (including geriatric patients): 2 inhalations of the aerosol, 4 times a day. If necessary, you can increase the dose up to a limit of 12 inhalations in a 24-hour period. Children: there is no experience with the use of Combivent in children below 12 years of age. You should immediately consult the doctor or seek the nearest hospital, in case of dyspnea of acute or rapidly worsening dyspnea (difficulty in breathing), if inhalations additional not to produce the improvement expected. – Overdose: symptoms: possible symptoms of overdosage are related basically to the salbutamol since ipratropium bromide is not absorbed after inhalation or oral administration and, therefore, should not cause phenomena of acute intoxication. The manifestations of overdosage with salbutamol include angina pectoris, hypertension, hipopotassemia and tachycardia. Treatment: the primary antidote for the treatment of overdosage with salbutamol is a agent beta-blocker cardiosseletivo. However, one should be cautious when administering this type of drug in patients with a history of bronchospasm.
What are the evils that can cause me?
in The same way with other beta-agonists, the side effects most frequently observed with the use of Combivent are slight tremor of skeletal muscles and nervousness. Can also occur, although less frequently, tachycardia, dizziness, palpitations and headache, especially in patients hypersensitive. Can occur hipopotassemia potentially serious as a result of therapy with beta-2-agonist. Have been reported isolated cases of local reactions, such as dryness of the mouth, throat irritation or allergic reactions. In the same way as with other bronchodilators, can occur cough, and, more rarely, bronchoconstriction paradoxical. The use of agents anticholinergics such as ipratropium bromide may cause urinary retention, particularly in patients with obstruction preexisting urinary flow.
Warnings and Precautions
what should I know before using?
Although rare, have been reported eye effects such as mydriasis, blurred vision and eye pain, when the contents of aerosols containing ipratropium bromide have reached inadvertently the eyes. Therefore, one should avoid the contact of Combivent in your eyes. If patients develop eye effects, should seek medical guidance. Patients should be instructed to comply with exactly the instructions for use of Combivent Aerosol. In the presence of cardiomyopathy obstructive hypertrophic taquiarritmia, diabetes mellitus not controlled, infarction recent infarction, disorders of organic cardiac or vascular serious and hyperthyroidism, Combivent Aerosol should only be employed after careful evaluation of risk/benefit, especially when used in doses above those recommended. Patients should be advised to seek medical advice immediately in case of dyspnea or acute worsening rapid dyspnea. If the obstruction bronchial asthma to worsen, it is very appropriate, and possibly hazardous to simply increase the use of Combivent in addition to the recommended dose, for extended periods of time. The therapeutic scheme of the patient should be reviewed when they are required in larger doses than usual for the control of symptoms. The treatment with beta-2-agonists can cause hipopotassemia potentially severe. Caution is recommended in case of respiratory obstruction severe, since this effect can be enhanced by the concomitant administration of derivatives xantínicos, steroids, and diuretics. Additionally, hypoxia may aggravate the effects of hipopotassemia about the heart rate. In these situations, it is recommended monitoring of serum levels, of potassium. Pregnancy and lactation: Combivent may only be used during pregnancy and lactation when the expected benefits justify the potential risks involved. – Drug interactions: beta-adrenergic agonists, corticosteroids and derivatives xantínicos can increase the effects of Combivent. The concomitant administration of other betamiméticos, anticholinergics and systemic derivatives xantínicos can increase the incidence of side effects. The concurrent use of beta-blockers can cause an important reduction of the negative effects of Combivent. On the other hand, Combivent may enhance the effects of anticholinergics or other drugs.